I was replying to Mouton's question/comment about why companies can launch a generic at-risk and not generally be subject to an injunction. The standard for granting a TRO or preliminary injunction is similar in that situation and the current one.
It's hard to get one in an at-risk launch and it's even harder (in my judgment) for Sanofi to get one here.
Market Data 
Markets 
AI
